Hemolytic uremic syndrome following Campath-1H induction

Transplant International

Volumn 20, Issue 4, 2007, Pages 386-389

  Bonatti, Hugo ^a   Brandacher, Gerald ^a   Boesmueller, Claudia ^a   Cont, Micol ^a   Hengster, Paul ^a   Rosenkranz, Alexander R ^b   Krugmann, Jens ^c   Margreiter, Raimund ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Campath 1H; Haemolytic uremic syndrome; Rapamycin; Renal transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CREATININE; METHYLPREDNISOLONE; NIFEDIPINE; RAPAMYCIN; STEROID; TACROLIMUS; URAPIDIL;

ADULT; ARTICLE; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; HEMOLYTIC UREMIC SYNDROME; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY GRAFT SWELLING; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SWELLING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PLASMA EXCHANGE; SIROLIMUS; TACROLIMUS;

EID: 33847223122     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00445.x     Document Type: Article

References (22)

1. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 2004; 17: 926.
2. Olie KH, Florquin S, Groothoff JW, et al. Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatr Nephrol 2004; 19: 1173.
3. Cheong HI, Lee BS, Kang HG, et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004; 19: 454.
4. Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol 2004; 121(Suppl.): S81
5. Franz M, Regele H, Schmaldienst S, Stummvoll HK, Horl WH, Pohanka E. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998; 66: 1258.
6. Abraham KA, Little MA, Dorman AM, Walshe JJ. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000; 13: 443.
7. Franco A, Hernandez D, Capdevilla L, et al. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003; 35: 1764.
8. Gatti S, Arru M, Reggiani P, et al. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation. J Nephrol 2003; 16: 586.
9. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
10. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant 2004; 18: 759.
11. Knechtle SJ, Pirsch JD, Fechner Jr J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
12. Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 1996; 35: 231.
13. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
14. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
15. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136: 754.
16. Schneeberger S, Kreczy A, Brandacher G, Steurer W, Margreiter R. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant 2004; 4: 1372.
17. Lin CC, King KL, Chao YW, Yang AH, Chang CF, Yang WC. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580.
18. Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 2002; 73: 756.
19. Rerolle JP, Akposso K, Lerolle N, et al. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000; 14: 262.
20. Lapointe M, Baillie GM, Bhaskar SS, et al. Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. Clin Transplant 1999; 13: 526.
21. Myers JN, Shabshab SF, Burton NA, Nathan SD. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999; 18: 1024.
22. Humar A, Jessurun J, Sharp HL, Gruessner RW. Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports. Transpl Int 1999; 12: 387.